<i>Bacillus licheniformis</i>: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications
<i>Bacillus licheniformis</i> produces several classes of antimicrobial substances, including bacteriocins, which are peptides or proteins with different structural composition and molecular mass: ribosomally synthesized by bacteria (1.4–20 kDa), non-ribosomally synthesized peptides and...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/7/1893 |
| _version_ | 1797587775011160064 |
|---|---|
| author | Margarita O. Shleeva Daria A. Kondratieva Arseny S. Kaprelyants |
| author_facet | Margarita O. Shleeva Daria A. Kondratieva Arseny S. Kaprelyants |
| author_sort | Margarita O. Shleeva |
| collection | DOAJ |
| description | <i>Bacillus licheniformis</i> produces several classes of antimicrobial substances, including bacteriocins, which are peptides or proteins with different structural composition and molecular mass: ribosomally synthesized by bacteria (1.4–20 kDa), non-ribosomally synthesized peptides and cyclic lipopeptides (0.8–42 kDa) and exopolysaccharides (>1000 kDa). Different bacteriocins act against Gram-positive or Gram-negative bacteria, fungal pathogens and amoeba cells. The main mechanisms of bacteriocin lytic activity include interaction of peptides with membranes of target cells resulting in structural alterations, pore-forming, and inhibition of cell wall biosynthesis. DNase and RNase activity for some bacteriocines are also postulated. Non-ribosomal peptides are synthesized by special non-ribosomal multimodular peptide synthetases and contain unnatural amino acids or fatty acids. Their harmful effect is due to their ability to form pores in biological membranes, destabilize lipid packaging, and disrupt the peptidoglycan layer. Lipopeptides, as biosurfactants, are able to destroy bacterial biofilms. Secreted polysaccharides are high molecular weight compounds, composed of repeated units of sugar moieties attached to a carrier lipid. Their antagonistic action was revealed in relation to bacteria, viruses, and fungi. Exopolysaccharides also inhibit the formation of biofilms by pathogenic bacteria and prevent their colonization on various surfaces. However, mechanism of the harmful effect for many secreted antibacterial substances remains unknown. The antimicrobial activity for most substances has been studied in vitro only, but some substances have been characterized in vivo and they have found practical applications in medicine and veterinary. The cyclic lipopeptides that have surfactant properties are used in some industries. In this review, special attention is paid to the antimycobacterials produced by <i>B. licheniformis</i> as a possible approach to combat multidrug-resistant and latent tuberculosis. In particular, licheniformins and bacitracins have shown strong antimycobacterial activity. However, the medical application of some antibacterials with promising in vitro antimycobacterial activity has been limited by their toxicity to animals and humans. As such, similar to the enhancement in the antimycobacterial activity of natural bacteriocins achieved using genetic engineering, the reduction in toxicity using the same approach appears feasible. The unique capability of <i>B. licheniformis</i> to synthesize and produce a range of different antibacterial compounds means that this organism can act as a natural universal vehicle for antibiotic substances in the form of probiotic cultures and strains to combat various types of pathogens, including mycobacteria. |
| first_indexed | 2024-03-11T00:43:39Z |
| format | Article |
| id | doaj.art-1dca1fd0188e42bda0c73cb2af259b79 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T00:43:39Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-1dca1fd0188e42bda0c73cb2af259b792023-11-18T20:55:18ZengMDPI AGPharmaceutics1999-49232023-07-01157189310.3390/pharmaceutics15071893<i>Bacillus licheniformis</i>: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical ApplicationsMargarita O. Shleeva0Daria A. Kondratieva1Arseny S. Kaprelyants2A.N. Bach Institute of Biochemistry, Federal Research Centre ‘Fundamentals of Biotechnology’, Russian Academy of Sciences, 119071 Moscow, RussiaA.N. Bach Institute of Biochemistry, Federal Research Centre ‘Fundamentals of Biotechnology’, Russian Academy of Sciences, 119071 Moscow, RussiaA.N. Bach Institute of Biochemistry, Federal Research Centre ‘Fundamentals of Biotechnology’, Russian Academy of Sciences, 119071 Moscow, Russia<i>Bacillus licheniformis</i> produces several classes of antimicrobial substances, including bacteriocins, which are peptides or proteins with different structural composition and molecular mass: ribosomally synthesized by bacteria (1.4–20 kDa), non-ribosomally synthesized peptides and cyclic lipopeptides (0.8–42 kDa) and exopolysaccharides (>1000 kDa). Different bacteriocins act against Gram-positive or Gram-negative bacteria, fungal pathogens and amoeba cells. The main mechanisms of bacteriocin lytic activity include interaction of peptides with membranes of target cells resulting in structural alterations, pore-forming, and inhibition of cell wall biosynthesis. DNase and RNase activity for some bacteriocines are also postulated. Non-ribosomal peptides are synthesized by special non-ribosomal multimodular peptide synthetases and contain unnatural amino acids or fatty acids. Their harmful effect is due to their ability to form pores in biological membranes, destabilize lipid packaging, and disrupt the peptidoglycan layer. Lipopeptides, as biosurfactants, are able to destroy bacterial biofilms. Secreted polysaccharides are high molecular weight compounds, composed of repeated units of sugar moieties attached to a carrier lipid. Their antagonistic action was revealed in relation to bacteria, viruses, and fungi. Exopolysaccharides also inhibit the formation of biofilms by pathogenic bacteria and prevent their colonization on various surfaces. However, mechanism of the harmful effect for many secreted antibacterial substances remains unknown. The antimicrobial activity for most substances has been studied in vitro only, but some substances have been characterized in vivo and they have found practical applications in medicine and veterinary. The cyclic lipopeptides that have surfactant properties are used in some industries. In this review, special attention is paid to the antimycobacterials produced by <i>B. licheniformis</i> as a possible approach to combat multidrug-resistant and latent tuberculosis. In particular, licheniformins and bacitracins have shown strong antimycobacterial activity. However, the medical application of some antibacterials with promising in vitro antimycobacterial activity has been limited by their toxicity to animals and humans. As such, similar to the enhancement in the antimycobacterial activity of natural bacteriocins achieved using genetic engineering, the reduction in toxicity using the same approach appears feasible. The unique capability of <i>B. licheniformis</i> to synthesize and produce a range of different antibacterial compounds means that this organism can act as a natural universal vehicle for antibiotic substances in the form of probiotic cultures and strains to combat various types of pathogens, including mycobacteria.https://www.mdpi.com/1999-4923/15/7/1893<i>Bacillus licheniformis</i><i>Mycobacterium tuberculosis</i>bacteriocinantimicrobial peptides |
| spellingShingle | Margarita O. Shleeva Daria A. Kondratieva Arseny S. Kaprelyants <i>Bacillus licheniformis</i>: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications Pharmaceutics <i>Bacillus licheniformis</i> <i>Mycobacterium tuberculosis</i> bacteriocin antimicrobial peptides |
| title | <i>Bacillus licheniformis</i>: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications |
| title_full | <i>Bacillus licheniformis</i>: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications |
| title_fullStr | <i>Bacillus licheniformis</i>: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications |
| title_full_unstemmed | <i>Bacillus licheniformis</i>: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications |
| title_short | <i>Bacillus licheniformis</i>: A Producer of Antimicrobial Substances, including Antimycobacterials, Which Are Feasible for Medical Applications |
| title_sort | i bacillus licheniformis i a producer of antimicrobial substances including antimycobacterials which are feasible for medical applications |
| topic | <i>Bacillus licheniformis</i> <i>Mycobacterium tuberculosis</i> bacteriocin antimicrobial peptides |
| url | https://www.mdpi.com/1999-4923/15/7/1893 |
| work_keys_str_mv | AT margaritaoshleeva ibacilluslicheniformisiaproducerofantimicrobialsubstancesincludingantimycobacterialswhicharefeasibleformedicalapplications AT dariaakondratieva ibacilluslicheniformisiaproducerofantimicrobialsubstancesincludingantimycobacterialswhicharefeasibleformedicalapplications AT arsenyskaprelyants ibacilluslicheniformisiaproducerofantimicrobialsubstancesincludingantimycobacterialswhicharefeasibleformedicalapplications |